Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield SD Avlayah Coverage | OpenP…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.06.32

    Avlayah (tividenofusp alfa-eknm)

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.06.32 alerts

    Get alerted when Policy 05.06.32 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of Avlayah for neurologic manifestations of mucopolysaccharidosis type II (MPS II). Avlayah is considered not medically necessary for all indications because available evidence is insufficient to demonstrate clinical efficacy.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyAvlayah (tividenofusp alfa-eknm)
    Policy CodePolicy 05.06.32
    Change TypeNo material change
    Effective DateJul 10, 2026
    Next Review DateN/A
    Key ActionCoverage is denied because Avlayah is not medically necessary for all indications due to insufficient evidence demonstrating clinical efficacy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Not medically necessaryCoverage stance for all indications
    15 mg/kg IV weeklyDose used in the clinical study
    47Pivotal study participants
    87%Infusion-related reactions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    91%
    CSF heparan sulfate reduction

    Coverage Criteria

    Not Medically Necessary

    Avlayah is considered not medically necessary for all indications.

    Not medically necessary: Avlayah (tividenofusp alfa-eknm) is not medically necessary for all indications, including the treatment of mucopolysaccharidosis type II (MPS II), due to insufficient evidence to demonstrate clinical efficacy.

    Applies to all indications, including MPS II.

    Avlayah (tividenofusp alfa-eknm) is considered not medically necessary for all indications, including treatment of mucopolysaccharidosis type II (MPS II), because there is insufficient evidence to demonstrate clinical efficacy.

    Procedures and Billing Codes

    Procedures and Billing CodesHCPCS
    C9399Unclassified drugs or biologicals
    J3490Unclassified drugs
    J3590Unclassified biologics

    Provider Guidance

    Denial Risk

    Insufficient evidence of clinical efficacy

    Coverage is denied because Avlayah (tividenofusp alfa-eknm) is considered not medically necessary for all indications, including treatment of MPS II, due to insufficient evidence to demonstrate clinical efficacy.

    Clinical Background

    Avlayah (tividenofusp alfa-eknm) is an enzyme replacement therapy for neurologic manifestations of MPS II, also known as Hunter syndrome. It is designed to cross the blood-brain barrier and deliver iduronate-2-sulfatase to the central nervous system.

    The therapy is intended for neurologic manifestations of MPS II, including use in presymptomatic or symptomatic pediatric patients weighing at least 5 kg before advanced neurologic impairment. The FDA approved the indication in March 2026 under accelerated approval based on reduction of cerebrospinal fluid heparan sulfate; however, clinical benefit has not been sufficiently demonstrated.

    Key Definitions

    Mucopolysaccharidosis type II (MPS II)
    ClassificationLysosomal storage disorder
    Also known asHunter syndrome
    ManifestationsNeurologic and peripheral manifestations
    Avlayah (tividenofusp alfa-eknm)
    Therapy typeEnzyme replacement therapy
    Active enzymeIduronate-2-sulfatase (IDS)
    Engineered componentTransferrin receptor (TfR)-binding Fc domain
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyAvlayah (tividenofusp alfa-eknm)
    Policy CodePolicy 05.06.32
    Change TypeNo material change
    Effective DateJul 10, 2026
    Next Review DateN/A
    Key ActionCoverage is denied because Avlayah is not medically necessary for all indications due to insufficient evidence demonstrating clinical efficacy.
    SourceLink
    On This Page
    Coverage CriteriaProcedures and Billing CodesProvider GuidanceClinical BackgroundKey Definitions
    Molecular structureFusion protein comprising IDS linked to an engineered TfR-binding Fc domain
    Intended deliveryDesigned to cross the blood-brain barrier and deliver IDS to the central nervous system